)
Actinogen Medical (ACW) investor relations material
Actinogen Medical Study result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Trial design
XanaMIA was a randomized, double-blind, placebo-controlled 36-week trial of Xanamem 10 mg daily in 247 patients with mild-to-moderate Alzheimer’s disease; primary endpoint was CDR-SB change at Week 36.
Mean age was 75.4 years in the Xanamem group and 73.4 in the placebo group; the prespecified over-75 subgroup comprised ~50% of participants.
Efficacy findings
Overall, Xanamem showed a 0.10-point CDR-SB benefit at Week 36, which was not statistically significant (p=0.65).
Interim Week 24 analysis showed a 0.58-point benefit (p=0.03) in 88 participants; this was not sustained in the final analysis.
In the prespecified over-75 subgroup, Xanamem showed 30% slowing of progression, with a 0.39-point CDR-SB difference at Week 36 (p=0.22).
Among participants over 75, 40% on Xanamem had no CDR-SB progression versus 22% on placebo; the stable-or-improved response difference was significant (p=0.02).
Cognition and daily-function endpoints numerically favored Xanamem; no clear signal was seen in the younger-than-75 subgroup.
Safety and open-label extension
Xanamem was well tolerated over 36 weeks, with no serious adverse events attributed to treatment.
The first 29 open-label participants reaching 24 weeks of active treatment showed mean CDR-SB disease stabilization; preliminary trends showed reductions in GFAP and neurofilament light, but not p-tau.
An update is expected in Q1 CY2027 when ~100 participants have completed at least 24 weeks of open-label treatment.
- XanaMIA results are due in November; pro forma cash is ~ $21.9m.ACW
Q1 2027 TU - Pivotal Alzheimer's trial results due November 2026; strong R&D focus and cash runway to mid-2027.ACW
H2 2026 - Xanamem's pivotal trial targets unmet Alzheimer's needs, with topline results due Nov 2026.ACW
Status update - Strong clinical progress and capital raise extend funding past key Alzheimer's trial results.ACW
Q3 2026 TU - Pivotal Alzheimer's trial surpasses key milestones; funding secured through late 2026.ACW
H2 2025 - Strong clinical progress and capital raises position the company for late-stage trials into 2025.ACW
H2 2024 - Positive interim trial results and FDA alignment drive clinical and financial momentum.ACW
H1 2026 - Interim trial success and AUD 12m raise support pivotal Alzheimer's results in late 2026.ACW
Investor update - Pivotal Alzheimer's trial on track, with strong safety, efficacy, and major milestones ahead.ACW
Corporate Presentation
)
)
)
)
)
)
)
)